SIRT1 and type 2 diabetes mellitus: Tilianin’s regulation of AMPK, PPARα, PPARγ, SIRT1, gut microbiota, BAT activity, glycogen synthesis, and inflammatory signaling underscores its potential as a multi-target therapeutic agent for metabolic disorders such as obesity, insulin resistance, type 2 diabetes, and MAFLD.